NO803918L - Fremgangsmaate ved fremstilling av nye estere av arginin - Google Patents
Fremgangsmaate ved fremstilling av nye estere av argininInfo
- Publication number
- NO803918L NO803918L NO803918A NO803918A NO803918L NO 803918 L NO803918 L NO 803918L NO 803918 A NO803918 A NO 803918A NO 803918 A NO803918 A NO 803918A NO 803918 L NO803918 L NO 803918L
- Authority
- NO
- Norway
- Prior art keywords
- arginine
- shock
- animals
- ester
- esters
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 9
- 239000004475 Arginine Substances 0.000 title description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title description 6
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000002148 esters Chemical class 0.000 claims description 15
- 230000035939 shock Effects 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 8
- 229930064664 L-arginine Natural products 0.000 claims description 8
- 235000014852 L-arginine Nutrition 0.000 claims description 8
- 239000002158 endotoxin Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 208000003455 anaphylaxis Diseases 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 206010002199 Anaphylactic shock Diseases 0.000 claims description 5
- 206010001029 Acute pulmonary oedema Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 102000013566 Plasminogen Human genes 0.000 claims 2
- 108010051456 Plasminogen Proteins 0.000 claims 2
- 235000019441 ethanol Nutrition 0.000 claims 2
- 150000007522 mineralic acids Chemical class 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 17
- 239000000126 substance Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 5
- 244000144993 groups of animals Species 0.000 description 4
- 108010039627 Aprotinin Proteins 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- -1 aliphatic alcohols Chemical class 0.000 description 3
- 235000020931 dietary conditions Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229960005356 urokinase Drugs 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000000988 hyperfibrinolytic effect Effects 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- KNIUHBNRWZGIQQ-UHFFFAOYSA-N 7-diethoxyphosphinothioyloxy-4-methylchromen-2-one Chemical compound CC1=CC(=O)OC2=CC(OP(=S)(OCC)OCC)=CC=C21 KNIUHBNRWZGIQQ-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT28416/79A IT1127321B (it) | 1979-12-28 | 1979-12-28 | Composizione farmaceutiche aventi specifiche proprieta' terapeutiche nei confronti dell'edema polmonare acuto,di alcuni stati di shock e dell'iperfibrinolisi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO803918L true NO803918L (no) | 1981-06-29 |
Family
ID=11223557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO803918A NO803918L (no) | 1979-12-28 | 1980-12-23 | Fremgangsmaate ved fremstilling av nye estere av arginin |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US4308280A (el) |
| JP (1) | JPS56100717A (el) |
| AR (1) | AR227297A1 (el) |
| AU (1) | AU529650B2 (el) |
| BE (1) | BE886759A (el) |
| BR (1) | BR8008492A (el) |
| CA (1) | CA1166160A (el) |
| DE (1) | DE3027056A1 (el) |
| DK (1) | DK523980A (el) |
| ES (1) | ES8205394A1 (el) |
| FI (1) | FI803995L (el) |
| FR (1) | FR2472387A1 (el) |
| GB (1) | GB2066073B (el) |
| GR (1) | GR72834B (el) |
| IE (1) | IE50550B1 (el) |
| IN (1) | IN151731B (el) |
| IT (1) | IT1127321B (el) |
| LU (1) | LU83028A1 (el) |
| NL (1) | NL8006706A (el) |
| NO (1) | NO803918L (el) |
| PH (1) | PH16250A (el) |
| PT (1) | PT72273B (el) |
| SE (1) | SE8009102L (el) |
| ZA (1) | ZA807514B (el) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112805A (en) * | 1985-11-22 | 1992-05-12 | Labsystems, Oy | Pharmaceutical preparation for promoting epithelial healing and prevention of epithelial destruction |
| IT1201511B (it) * | 1985-12-23 | 1989-02-02 | Italfarmaco Spa | Derivati citoprotettivi in patologie a base ischemica,loro preparazione e composizioni che li cntengono |
| GB8929076D0 (en) * | 1989-12-22 | 1990-02-28 | Scras | Treatment of shock by blocking agents of edrf effect or formation |
| SE468881B (sv) * | 1991-01-09 | 1993-04-05 | Kabi Pharmacia Ab | Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar |
| US5436270A (en) * | 1993-04-07 | 1995-07-25 | National Science Council | Method for protecting against endotoxin-induced shock |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US20050148669A1 (en) * | 2004-10-21 | 2005-07-07 | Daniel Amato | Amino acid esters as nutrient supplements and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB897439A (en) * | 1959-05-08 | 1962-05-30 | American Cyanamid Co | Compositions for intravenous use for blood clot lysis |
| JPS514125A (en) * | 1974-06-27 | 1976-01-14 | Mitsubishi Chem Ind | N22 ashiru ll arugininesuterumatahasono sanfukaenno seizoho |
-
1979
- 1979-12-28 IT IT28416/79A patent/IT1127321B/it active
-
1980
- 1980-06-23 US US06/162,008 patent/US4308280A/en not_active Expired - Lifetime
- 1980-07-17 DE DE19803027056 patent/DE3027056A1/de not_active Ceased
- 1980-12-02 ZA ZA00807514A patent/ZA807514B/xx unknown
- 1980-12-02 GR GR63523A patent/GR72834B/el unknown
- 1980-12-03 CA CA000366100A patent/CA1166160A/en not_active Expired
- 1980-12-03 AU AU65028/80A patent/AU529650B2/en not_active Ceased
- 1980-12-04 AR AR283475A patent/AR227297A1/es active
- 1980-12-05 ES ES497509A patent/ES8205394A1/es not_active Expired
- 1980-12-09 DK DK523980A patent/DK523980A/da not_active Application Discontinuation
- 1980-12-10 NL NL8006706A patent/NL8006706A/nl not_active Application Discontinuation
- 1980-12-11 IN IN1367/CAL/80A patent/IN151731B/en unknown
- 1980-12-12 IE IE2606/80A patent/IE50550B1/en unknown
- 1980-12-15 PH PH24981A patent/PH16250A/en unknown
- 1980-12-18 GB GB8040637A patent/GB2066073B/en not_active Expired
- 1980-12-19 BE BE2/58914A patent/BE886759A/nl not_active IP Right Cessation
- 1980-12-22 LU LU83028A patent/LU83028A1/de unknown
- 1980-12-22 FI FI803995A patent/FI803995L/fi not_active Application Discontinuation
- 1980-12-23 SE SE8009102A patent/SE8009102L/xx not_active Application Discontinuation
- 1980-12-23 BR BR8008492A patent/BR8008492A/pt unknown
- 1980-12-23 NO NO803918A patent/NO803918L/no unknown
- 1980-12-23 PT PT72273A patent/PT72273B/pt unknown
- 1980-12-24 FR FR8027469A patent/FR2472387A1/fr active Granted
- 1980-12-26 JP JP18943680A patent/JPS56100717A/ja active Granted
-
1981
- 1981-08-27 US US06/296,830 patent/US4405643A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IE802606L (en) | 1981-06-28 |
| AU529650B2 (en) | 1983-06-16 |
| FI803995L (fi) | 1981-06-29 |
| ZA807514B (en) | 1981-11-25 |
| FR2472387A1 (fr) | 1981-07-03 |
| JPS56100717A (en) | 1981-08-12 |
| FR2472387B1 (el) | 1983-10-07 |
| JPS6342603B2 (el) | 1988-08-24 |
| BR8008492A (pt) | 1981-07-14 |
| PH16250A (en) | 1983-08-16 |
| IN151731B (el) | 1983-07-16 |
| GB2066073B (en) | 1984-02-01 |
| PT72273A (en) | 1981-01-01 |
| PT72273B (en) | 1981-11-05 |
| LU83028A1 (de) | 1981-03-27 |
| SE8009102L (sv) | 1981-06-29 |
| US4308280A (en) | 1981-12-29 |
| US4405643A (en) | 1983-09-20 |
| DK523980A (da) | 1981-06-29 |
| ES497509A0 (es) | 1982-06-16 |
| GB2066073A (en) | 1981-07-08 |
| IT7928416A0 (it) | 1979-12-28 |
| BE886759A (nl) | 1981-04-16 |
| AR227297A1 (es) | 1982-10-15 |
| IT1127321B (it) | 1986-05-21 |
| ES8205394A1 (es) | 1982-06-16 |
| DE3027056A1 (de) | 1981-07-02 |
| GR72834B (el) | 1983-12-07 |
| AU6502880A (en) | 1981-07-02 |
| NL8006706A (nl) | 1981-07-16 |
| IE50550B1 (en) | 1986-05-14 |
| CA1166160A (en) | 1984-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4267194A (en) | Calcium derivatives of taurine having reinforced neuro-muscular activity | |
| EP0167115B1 (en) | New derivatives of l-carnitine | |
| KR840003414A (ko) | 3-히드록시부탄산 또는 이 산으로부터 유도된 염을 함유하는 약학적 조성물과, 의약품으로 사용할 수 있는 3-히드록시부탄산으로부터 유도된 화합물 | |
| JPH0524135B2 (el) | ||
| IE813104L (en) | Method and compounds for treating inflammatory bowel¹disease | |
| SU1015820A3 (ru) | Способ получени производных 9-аминоалкилфлуоренов или их солей | |
| NO803918L (no) | Fremgangsmaate ved fremstilling av nye estere av arginin | |
| GB1583691A (en) | Benzopyrans | |
| EP0177356B1 (en) | Method for treatment of antidiuresis | |
| Ashbolt et al. | The action of diisopropyl phosphorofluoridate and other anticholinesterases on amino acids | |
| Sabin et al. | The therapeutic effectiveness of a practically nontoxic new compound (calcium aurothiomalate) in experimental, proliferative, chronic arthritis of mice | |
| US4124724A (en) | Crystalline caffeic acid derivatives and compositions and method for treating snakebite | |
| US4138432A (en) | Amides of phosphonoacetic acid | |
| US4022907A (en) | Pharmaceutical compositions containing 1,3-dithiacycloalkylidene malonates | |
| DE2909742A1 (de) | Neue derivate des phenyl-alanins, deren herstellung, sowie deren therapeutische verwendung | |
| JPH03188088A (ja) | 新規リゾホスファチジルセリン | |
| US4329290A (en) | Antithrombotic derivatives of ammonium ascorbate | |
| US4092412A (en) | Treatment of herpes simplex infections | |
| US4080467A (en) | Pharmaceutical compositions comprising 1,3-dithiolan-2-ylidene malonate derivatives | |
| JPS6338322B2 (el) | ||
| EP0491103B1 (en) | Compositions for therapeutic use comprising organogermanium derivatives | |
| Weil et al. | Conservation of the biological activity of a soluble ribonucleic acid | |
| US3461211A (en) | Lipotropic compositions and their administration | |
| US4727164A (en) | Mixture of esters of para amino benzoic acid and ascorbic acid | |
| JPS5724337A (en) | Aminocarboxylic acid derivative, its preparation, and antitumor agent containing the same as active principle |